Asthma app study data on ResearchKit shows mixed results for patient … – MedCity News


MedCity News

Asthma app study data on ResearchKit shows mixed results for patient
MedCity News
The company, a spin-off of LifeMap Sciences, noted that preliminary data for Asthma Health showed that more than half of users “not only complete the e-consent process, they also come back the very next day to use the app. This is a very high rate of

and more »

View full post on asthma – Google News

Mixed opinions on Toronto mayor’s medical disclosure – CTV News


National Post

Mixed opinions on Toronto mayor's medical disclosure
CTV News
Torontonians were informed of the allergic reaction that exacerbated Ford's asthma and prompted him to seek medical attention. The mayor's brother Doug Ford told reporters the mayor had been advised to redouble his efforts to lose weight once he was in
Rob Ford in hospital after complications from asthma, mayor's office confirmsNational Post
Toronto Mayor Rob Ford hospitalized because of asthma issue, office saysToronto Star

all 109 news articles »

View full post on asthma – Google News

Targacept slips on mixed results from drug studies – BusinessWeek

Targacept slips on mixed results from drug studies
BusinessWeek
Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were treated with TC-6987 for
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of MarketWatch (press release)
Targacept discontinues two clinical trials, reports success with a thirdWinston-Salem Journal (blog)
Asthma drug shows promise, diabetes study fails in Targacept phase 2 trialsMedCity News

all 41 news articles »

View full post on asthma – Google News

Targacept reports mixed data from two trials – Reuters

Targacept reports mixed data from two trials
Reuters
* Says asthma trial meets main goals * Says diabetes trial did not meet main goal * Targacept drops development of drug for diabetes March 27 (Reuters) – Targacept said an experimental drug proved effective in a mid-stage asthma trial, but failed to
Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of MarketWatch (press release)
Targacept Dropping Development Of Diabetes Drug; Shares FallWall Street Journal
Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987RTT News

all 14 news articles »

View full post on asthma – Google News

Relovair COPD and asthma filings on track despite more mixed trial results – The Pharma Letter


Proactive Investors USA & Canada

Relovair COPD and asthma filings on track despite more mixed trial results
The Pharma Letter
For asthma, the company plans to file for approval in Europe in mid-2012 and will continue discussions with the US Food and Drug Administration on the regulatory requirements for a US asthma indication. GSK is looking to replace its top-selling drug
Relovair on track for filing in mid-2012, says GSKPMLiVE
GSK, Theravance Report Mixed Bag of Data for Relovair in COPD, AsthmaGenetic Engineering News
GSK and Theravance Announce Completion of the Relovair(TM)* Registrational MarketWatch (press release)
Reuters –MedCity News –FierceBiotech
all 36 news articles »

View full post on asthma – Google News

Grading the Severity of Obstruction in Mixed Obstructive-Restrictive Lung Disease.

Grading the Severity of Obstruction in Mixed Obstructive-Restrictive Lung Disease.

Chest. 2011 Mar 17;

Authors: Gardner ZS, Ruppel GL, Kaminsky DA

ABSTRACT BACKGROUND: The severity of obstructive pulmonary disease is determined by the percent predicted FEV(1) based on ATS/ERS guidelines. In patients with coexisting restrictive lung disease, the decrease in FEV(1) can overestimate the degree of obstruction. We hypothesize that adjusting the FEV(1) for the decrease in TLC results in a more appropriate grading of the severity of obstruction. METHODS: We examined a large PFT database and identified patients with both restrictive (TLC < 80% predicted) and obstructive (FEV(1)/FVC < the lower limit of normal) lung disease. FEV(1) percent predicted was adjusted for the degree of restriction by dividing it by percent predicted TLC. We compared the distribution of severity grading between adjusted and unadjusted values according to ATS/ERS criteria, and determined how the distribution of severity would change based on asthma and COPD guidelines. RESULTS: We identified 199 patients with coexisting restrictive and obstructive lung disease. By ATS/ERS grading, the unadjusted data categorized 76% of patients as having severe or very severe obstruction, and 11% as having mild or moderate obstruction. The adjusted data classified 33% with severe or very severe obstruction, and 44% with mild or moderate obstruction. Of the corrected values, 83% resulted in a change to less severe obstruction by ATS/ERS guidelines, and 44% and 70% of patients, respectively, would be reclassified as having less severe obstruction by current asthma and COPD guidelines. CONCLUSIONS: This method results in a more appropriate distribution of severity of obstruction, which should lead to more accurate treatment of obstruction in these patients.

PMID: 21415132 [PubMed – as supplied by publisher]

View full post on pubmed: asthma